Methods:To make the model of hepatic cirrhosis by composite factors,compared with Fufangbiejiaruangan tablet,the effect of RGXZ liquid on hepatic tissue pathological histology and the content of IL-1β and IL-6 in serum and liver tissue were observed.
Objectives: Liver fibrosis is an inevitable stage of chronic liver diseases developing into hepatic cirrhosis and the pathological basis is excessive deposition and abnormal distribution of the extracellular matrix(ECM).
[WT5”HZ]Methods [WT5”BZ]41 patients with chronic hepatitis and early hepatic cirrhosis took Han-Dan-Gan-Le 1.6g, three times one day, 3 months as a course of treatment. The level of TNF-α,sIL-2R,SOD,SF,Ig and C 3 in serum were detected before and after the treatment.
Postoperative hepatic insulin-like growth factor-1 (IGF-1) production may be severely disturbed in patients with liver cirrhosis.
Patients with advanced liver cirrhosis frequently develop the hepatorenal syndrome, a condition characterized by renal failure, marked reduction in renal blood flow and overactivity of endogenous vasoactive systems.
Second, for differential diagnosis of renal failure in liver cirrhosis, an algorithm was developed and the criteria defining the presence of a HRS are given.
The study offered a strong evidence for discrimination of liver cirrhosis in PEM.
Regarding infusion therapy, we were mainly interested in whether an amino acid solution adapted to the metabolism in liver cirrhosis causes an accumulation of BCAA in muscle or modifies the intracellular content of glutamate and glutamine.
The search for biochemical predictors of the NAT2 phenotype to optimize prophylaxis and pharmacotherapy of hepatic cirrhosis
Of them, 84.4% were associated with hepatic cirrhosis.
These results indicated that activated C-erbB-2, N-ras and altered p53 genes may have a role in human HCC pathogenesis through promiting the development of HCC from hepatic cirrhosis and the progression of HCC.
Conclusion: iNOS and eNOS may play a role in malignant transformation f post-hepatic cirrhosis.
Secondary medical management in PBC should address the treatment of complications of chronic cholestasis, hepatic cirrhosis, and liver failure.